SCYNEXIS Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy SCYNEXIS Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for SCYNEXIS Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for SCYNEXIS Inc. is SCYX:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
SCYNEXIS Inc. has its primary listing on NASDAQ. You can trade SCYNEXIS Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, SCYNEXIS Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include SCYNEXIS Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like SCYNEXIS Inc..